[go: up one dir, main page]

WO2008061966A8 - Nouvelle utilisation de la flibansérine - Google Patents

Nouvelle utilisation de la flibansérine

Info

Publication number
WO2008061966A8
WO2008061966A8 PCT/EP2007/062527 EP2007062527W WO2008061966A8 WO 2008061966 A8 WO2008061966 A8 WO 2008061966A8 EP 2007062527 W EP2007062527 W EP 2007062527W WO 2008061966 A8 WO2008061966 A8 WO 2008061966A8
Authority
WO
WIPO (PCT)
Prior art keywords
flibanserin
new use
sub
medicament
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/062527
Other languages
English (en)
Other versions
WO2008061966A2 (fr
WO2008061966A3 (fr
Inventor
Angelo Ceci
Marcus Schindler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of WO2008061966A2 publication Critical patent/WO2008061966A2/fr
Publication of WO2008061966A3 publication Critical patent/WO2008061966A3/fr
Publication of WO2008061966A8 publication Critical patent/WO2008061966A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de la flibansérine dans la préparation d'un médicament pour traiter des maladies pour lesquelles l'utilisation de doses thérapeutiques efficaces de composés possédant une affinité avec le récepteur 5-HT2B présente un avantage thérapeutique.
PCT/EP2007/062527 2006-11-22 2007-11-20 Nouvelle utilisation de la flibansérine Ceased WO2008061966A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124575.9 2006-11-22
EP06124575 2006-11-22

Publications (3)

Publication Number Publication Date
WO2008061966A2 WO2008061966A2 (fr) 2008-05-29
WO2008061966A3 WO2008061966A3 (fr) 2008-07-10
WO2008061966A8 true WO2008061966A8 (fr) 2008-09-04

Family

ID=39201544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062527 Ceased WO2008061966A2 (fr) 2006-11-22 2007-11-20 Nouvelle utilisation de la flibansérine

Country Status (1)

Country Link
WO (1) WO2008061966A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324247B2 (en) 2008-10-22 2012-12-04 Ventrus Biosciences, Inc. Method for treating pulmonary arterial hypertension
CN103467596A (zh) * 2012-06-06 2013-12-25 北京大学 一个治疗肺动脉高压的新靶点

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040107B1 (hr) * 2001-08-02 2012-02-29 Bidachem S.P.A. Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20060120972A1 (en) * 2004-11-09 2006-06-08 Peter Engels 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension

Also Published As

Publication number Publication date
WO2008061966A2 (fr) 2008-05-29
WO2008061966A3 (fr) 2008-07-10

Similar Documents

Publication Publication Date Title
MX2010014234A (es) Compuestos pirazol 436.
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
IL201479A (en) Use of tapentadol for the preparation of pain medication
WO2007131072A3 (fr) Substances thérapeutiques contenant du bore résistant à l'hydrolyse et méthodes d'utilisation
WO2012021629A3 (fr) Nouveaux agonistes du récepteur dopaminergique d3 pour traiter la dyskinésie dans la maladie de parkinson
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
TW200639156A (en) New compounds
TW200745122A (en) New compounds I
TNSN08506A1 (en) Substituted carboxamides
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
DE602007007934D1 (en) Imidazoazephinonverbindungen
WO2008061966A8 (fr) Nouvelle utilisation de la flibansérine
EP4218786A3 (fr) Opiorphine destinée à être utilisée comme agent analgésique
ECSP088588A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
EP2124554A4 (fr) Compositions et procédés pour le traitement du cancer
MX2009004178A (es) Conjugados peptidicos citotoxicos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07847216

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07847216

Country of ref document: EP

Kind code of ref document: A2